Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
|||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *6/27/2018: Initial FDA approval in combination with [[Encorafenib (Braftovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. | + | *6/27/2018: Initial FDA approval in combination with [[Encorafenib (Braftovi)]] for patients with unresectable or metastatic [[melanoma]] with a [[Biomarkers#BRAF|BRAF]] [[Biomarkers#V600E|V600E]] or [[Biomarkers#V600K|V600K mutation]], as detected by an FDA-approved test. ''(Based on [https://clinicaltrials.gov/ct2/show/NCT01909453 COLUMBUS])'' |
==Also known as== | ==Also known as== | ||
Revision as of 00:37, 21 April 2021
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLUMBUS)
Also known as
- Code names: ARRY-162, ARRY-438162, MEK162
- Brand names: Braftovi, Mektovi